Do AD drugs attempt to reduce the concentration of APOE in the brain? If so, is it known if these drugs either failed to reduce the concentration of APOE, or succeeded in reducing concentration but still didn't work?
“Reduce APOE” is an oversimplified view. The mechanisms by which the AD-associated E4 genotype (arg112, arg158) results in disease are still poorly understood. The main therapeutic hypothesis for AD is to reduce the levels of pathogenic plaques and aggregates using antibodies.